SEC Filing Summary: Obalon Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (Ticker: OBLN) on September 16, 2020, reporting on the results of its 2020 Annual Meeting of Stockholders held on the same date. The registrant is an emerging growth company incorporated in Delaware. Note: The request metadata references "Vyome Holdings, Inc," but the filing text explicitly identifies the registrant as Obalon Therapeutics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected three Class I Directors for a term expiring at the 2023 annual meeting.
- Douglas Fisher, M.D.: 2,012,617 votes For; 91,194 votes Withheld.
- Sharon Stevenson, DVM Ph.D.: 2,012,248 votes For; 91,563 votes Withheld.
- William Plovanic: 2,004,282 votes For; 99,529 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Votes For: 5,098,733
- Votes Against: 141,919
- Abstentions: 31,191
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document serves solely to disclose the final voting results of the Annual Meeting.
Key Facts for Investor Verification
- Confirm the identity of the registrant as Obalon Therapeutics, Inc., distinct from Vyome Holdings, Inc.
- Verify the successful ratification of KPMG LLP as the independent auditor for the 2020 fiscal year.
- Note the significant number of broker non-votes (3,168,032) recorded for the director elections.
- Review the definitive proxy statement on Schedule 14A (filed August 7, 2020) for detailed background on the director nominees and auditor appointment.